| 1 |
34966123 | Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. | 2022 Mar 1 |
1 |
| 2 |
33919958 | Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. | 2021 Apr 14 |
1 |
| 3 |
34059487 | A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. | 2021 Aug |
2 |
| 4 |
34251414 | Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). | 2021 Jul 13 |
1 |
| 5 |
32171069 | Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. | 2020 Apr |
1 |
| 6 |
32687450 | Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. | 2020 Oct 20 |
2 |
| 7 |
30535449 | Cyr61 decreases Cytarabine chemosensitivity in acute lymphoblastic leukemia cells via NF-κB pathway activation. | 2019 Feb |
1 |
| 8 |
30813354 | Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. | 2019 Feb 22 |
2 |
| 9 |
31881855 | In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells. | 2019 Dec 27 |
1 |
| 10 |
29477371 | Venetoclax: A new wave in hematooncology. | 2018 May |
1 |
| 11 |
29872325 | miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells. | 2018 |
1 |
| 12 |
30361682 | Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML. | 2018 Oct 25 |
1 |
| 13 |
27922189 | Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity. | 2017 Jun |
2 |
| 14 |
28721010 | Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway. | 2017 |
1 |
| 15 |
28810561 | Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression. | 2017 Aug |
3 |
| 16 |
26028971 | Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3-D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells. | 2015 |
3 |
| 17 |
26375587 | Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. | 2015 |
1 |
| 18 |
24342948 | BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. | 2014 May |
1 |
| 19 |
23320492 | Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. | 2013 Apr |
3 |
| 20 |
24370051 | [Effect of salidroside on apoptosis of bone marrow mesenchymal stem cells induced by ara-C]. | 2013 Dec |
1 |
| 21 |
22209977 | miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. | 2012 Apr |
1 |
| 22 |
21212792 | The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. | 2011 Mar |
3 |
| 23 |
19204830 | Small hairpin RNA targeting at Bcl-2 increases cytarabine-induced apoptosis in Raji cells. | 2009 Feb |
7 |
| 24 |
17490525 | [Effect of nimodipine on mechanisms of HL-60 cell apoptosis induced by cytarabine]. | 2007 Feb |
2 |
| 25 |
16112192 | Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. | 2006 Mar |
2 |
| 26 |
16219908 | Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. | 2006 Jan |
4 |
| 27 |
16129037 | [Study on mechanism of apoptosis of HL-60 cells induced by cytarabine]. | 2005 Aug |
2 |
| 28 |
15631654 | [A novel bcl-2 antisense oligodeoxynucleotide F951 increases sensitivity of HL-60 cells to Ara-C]. | 2004 Dec |
1 |
| 29 |
12488556 | Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. | 2003 Jan |
1 |
| 30 |
12667288 | [Design of antisense oligodeoxynucleotide targeting at bcl-2 mRNA and observation on its effect on the sensitivity of leukemia cells to arabinosyl cytosine]. | 2003 Feb |
6 |
| 31 |
12853972 | Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation. | 2003 Jul 10 |
1 |
| 32 |
12931228 | HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. | 2003 Nov |
1 |
| 33 |
12170773 | Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. | 2002 Mar-Apr |
1 |
| 34 |
12520735 | [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells]. | 2002 Dec |
4 |
| 35 |
12533044 | Chemotherapy induces bcl-2 cleavage in lymphoid leukemic cell lines. | 2002 Nov |
2 |
| 36 |
11299723 | Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities. | 2001 Jan-Feb |
1 |
| 37 |
11351258 | Resistance of human leukemic cell lines to 1-beta-D-arabinofuranosylcytosine: characterization of an experimental model. | 2001 Jun |
1 |
| 38 |
11848518 | Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. | 2001 Sep-Oct |
1 |
| 39 |
10769646 | Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. | 2000 Jan-Feb |
6 |
| 40 |
10845930 | Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. | 2000 Jun 15 |
4 |
| 41 |
10997587 | Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. | 2000 Aug |
1 |
| 42 |
11020446 | Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). | 2000 Nov 15 |
3 |
| 43 |
10023011 | Bcl-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis. | 1999 Mar-Apr |
3 |
| 44 |
10456672 | Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells. | 1999 Aug |
3 |
| 45 |
10500808 | BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance. | 1999 |
1 |
| 46 |
10500809 | Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. | 1999 |
2 |
| 47 |
10557066 | Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. | 1999 Nov |
3 |
| 48 |
9338077 | Ara-C: cellular and molecular pharmacology. | 1998 |
1 |
| 49 |
9699642 | "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. | 1998 Aug 1 |
4 |
| 50 |
9840183 | An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. | 1998 Dec |
1 |